Loading... Please wait... Loading... Please wait...
ESTIMATED
03/14/2024
03/14/2024
(AS OF MARCH 31)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 0 | -$0.10 | -$0.10 | -$0.10 |
| Q2 2024 | 1 | -$0.11 | -$0.11 | -$0.11 |
| Q3 2024 | 0 | -$0.10 | -$0.10 | -$0.10 |
| Q4 2024 | 0 | -$0.06 | -$0.06 | -$0.06 |
| Q1 2025 | 0 | -$0.08 | -$0.08 | -$0.08 |
| Q2 2025 | 0 | -$0.10 | -$0.10 | -$0.10 |
ImmunoPrecise Antibodies Ltd. last posted its earnings results on Thursday, March 14th, 2024. The company reported $-0.08 earnings per share for the quarter, missing analysts' consensus estimates of $-0.08 by $0. The company had revenue of 6.22 M for the quarter and had revenue of 20.67 M for the year. ImmunoPrecise Antibodies Ltd. has generated $-1 earnings per share over the last year ($-1.07 diluted earnings per share) and currently has a price-to-earnings ratio of -1.75. ImmunoPrecise Antibodies Ltd. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Friday, July 5th, 2024 based on prior year's report dates.
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue | 01/30/2024 | Q3 2023 | -$0.11 | $6.07 M | $6.22 M | 02/15/2024 | Q2 2023 | -$0.10 | $5.80 M | $6.15 M | 08/14/2023 | Q1 2023 | -$0.38 | $4.69 M | 04/29/2023 | Q4 2022 | -$0.20 | $5.74 M | $5.62 M | 01/30/2023 | Q3 2022 | -$0.19 | $5.45 M | $5.17 M | 08/14/2023 | Q2 2022 | -$0.30 | $5.18 M | 07/30/2022 | Q1 2022 | -$0.38 | $5.31 M | $4.69 M | 04/29/2022 | Q4 2021 | -$0.22 | $4.99 M | $5.24 M | 01/30/2022 | Q3 2021 | -$0.20 | $3.93 M | $4.82 M | 10/30/2021 | Q2 2021 | -$0.26 | $4.04 M | $4.72 M | 09/09/2021 | Q1 2021 | -$0.17 | $4.81 M | $4.59 M | 04/29/2021 | Q4 2020 | -$0.30 | $4.88 M | 02/03/2021 | Q3 2020 | -$0.08 | $4.54 M | $4.52 M | 10/30/2020 | Q2 2020 | -$0.03 | $3.57 M | $4.75 M | 07/30/2020 | Q1 2020 | -$0.04 | $2.84 M | $3.76 M | 04/29/2020 | Q4 2019 | -$0.07 | $4.15 M | 01/30/2020 | Q3 2019 | -$0.05 | $2.80 M | $4.03 M | 10/30/2019 | Q2 2019 | -$0.10 | $2.74 M | $3.16 M | 07/30/2019 | Q1 2019 | -$0.15 | $2.67 M | $2.72 M | 04/29/2019 | Q4 2018 | -$0.29 | $2.64 M |
|---|
A. ImmunoPrecise Antibodies Ltd. has not confirmed its next earnings publication date, but the company's estimated earnings date is Friday, July 5th, 2024 based off last year's report dates.
A. The conference call for ImmunoPrecise Antibodies Ltd.'s latest earnings report can be listened to online.
A. The conference call transcript for ImmunoPrecise Antibodies Ltd.'s latest earnings report can be read online.
A. ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) has a recorded annual revenue of $20.67 M.
A. ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) has a recorded net income of $20.67 M. ImmunoPrecise Antibodies Ltd. has generated $-1.07 earnings per share over the last four quarters.
A. ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) has a price-to-earnings ratio of -1.75 and price/earnings-to-growth ratio is -0.1.
